

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 4th July 2025

FOI Ref No 29455

Requested Information:

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
 - Dostarlimab (Jemperli)
 - Dostarlimab (Jemperli) AND Chemotherapy
 - Hormone therapy (Progesterone or Letrozole)
 - Pembrolizumab (Keytruda) monotherapy
 - Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Any other SACT
 - Any other Chemotherapy
 - Durvalumab with platinum-based chemotherapy
 - Pembrolizumab with platinum-based chemotherapy
3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?
4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
 - Dostarlimab (Jemperli) AND Chemotherapy
 - Durvalumab with platinum-based chemotherapy
 - Pembrolizumab with platinum-based chemotherapy
 - Hormone therapy (Progesterone or Letrozole)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Any other SACT
 - Any other chemotherapy
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

Response:

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? **Yes**

Data from March 2025 to June 2025

2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
 - Dostarlimab (Jemperli) **0**
 - Dostarlimab (Jemperli) AND Chemotherapy **2**
 - Hormone therapy (Progesterone or Letrozole) **7**
 - Pembrolizumab (Keytruda) monotherapy **0**
 - Lenvatinib + Pembrolizumab (Lenvima +Keytruda) **7**
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) **9**
 - Any other SACT:
 - Doxorubicin **1**
 - Paclitaxel **1**
 - Any other Chemotherapy **as above**
 - Durvalumab with platinum-based chemotherapy **0**
 - Pembrolizumab with platinum-based chemotherapy **0**
3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? **6**
4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
 - Dostarlimab (Jemperli) AND Chemotherapy **2**
 - Durvalumab with platinum-based chemotherapy **0**
 - Pembrolizumab with platinum-based chemotherapy **0**
 - Hormone therapy (Progesterone or Letrozole) **5**
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) **9**
 - Any other SACT **0**
 - Any other chemotherapy **0**
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?
 - **Please view appendix one.**

Attachment(s):

Appendix One – FOI Ref 29455 Endometrial Cancer Clinical Trials

Date Response sent: 7th August 2025